Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 MilestonesGlobeNewsWire • 01/07/24
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)GlobeNewsWire • 01/04/24
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman SyndromeGlobeNewsWire • 01/03/24
Does Ultragenyx (RARE) Have the Potential to Rally 87.43% as Wall Street Analysts Expect?Zacks Investment Research • 01/02/24
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)GlobeNewsWire • 12/18/23
Ultragenyx (RARE) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/02/23
Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate UpdateGlobeNewsWire • 10/26/23
Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/25/23
Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 10/23/23
Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?Zacks Investment Research • 10/17/23
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson DiseaseGlobeNewsWire • 10/16/23
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)GlobeNewsWire • 10/14/23
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)GlobeNewsWire • 10/09/23
Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023GlobeNewsWire • 10/05/23
Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)GlobeNewsWire • 09/25/23
Ultragenyx (RARE) Soars 6.1%: Is Further Upside Left in the Stock?Zacks Investment Research • 09/08/23